Usage of HOXA7 and HOXA9 methylation detection reagents in preparation of lung cancer diagnostic reagents

Abstract

The invention belongs to the field of genetic diagnosis, and relates to application of detection reagents, which use sputum as test samples as well as methylation of HOXA7 and HOXA9 as detect targets,in preparation of lung cancer diagnostic reagents. For the first time, the invention utilizes the HOXA7 and the HOXA9 in the sputum together as a tumor marker for lung cancer detection; and the tumormarker in the sputum has a sensitivity up to 97.1% and a specificity up to 90.9%, so that the tumor marker has higher detection sensitivity compared with existing reported tumor markers of the lung cancer. Especially for adenocarcinoma, the detection sensitivity of the tumor marker is even as high as 100%, so that the tumor marker is of very great application values to adenocarcinoma detection and diagnosis.

Description

technical field [0001] The invention belongs to the field of gene diagnosis, and more specifically, the invention relates to the application of a human HOXA7 and human HOXA9 gene methylation detection reagent in the preparation of lung cancer diagnostic reagents, and a method for human HOXA7 gene and HOXA9 gene methylation detection. [0002] technical background [0003] Lung cancer is a malignant tumor of the lung originating from the bronchial mucosa, glands or alveolar epithelium. According to the pathological type, it can be divided into: 1. Small cell lung cancer (SCLC): a special pathological type of lung cancer, with obvious tendency of distant metastasis and poor prognosis, but most patients are sensitive to radiotherapy and chemotherapy. 2. Non-small cell lung cancer (NSCLC): other pathological types of lung cancer other than small cell lung cancer, including squamous cell carcinoma, adenocarcinoma, large cell carcinoma, etc. There are certain differences in biolog...

AI Technical Summary

Problems solved by technology

(4) Bone scan: the sensitivity of detection of bone metastases of lung cancer is high, but there is a certain false positive rate

If an early tumor screening product cannot screen out all or most of the patients, those who miss the test will not be able to receive sufficient risk warnings, thus delaying the timing of treatment, which is a huge loss for patients loss

[0018] Although some tumor markers related to lung cancer have been found in the prior art, the sensitivity and specificity of these tumor markers cannot meet the demand due to the limitation of detection reagents or detection methods for these tumor markers. Therefore, the current There is still a need for further research in the field of screening methods that can actually be applied to lung cancer

However, although non-invasive screening has unique advantages in sampling, it also has some limitations in other aspects, such as adenocarcinoma in lung cancer, which is difficult to cough up through sputum due to exfoliated cells in the deep lung Generally speaking, those skilled in the art would think that this type of lung cancer is not suitable for non-invasive screening

On the other hand, even for other types of lung cancer, the currently reported non-invasive screening methods are difficult to meet the requirements of clinical use

Although relevant research has been progressing for many years, there is still no non-invasive screening method for lung cancer that can be promoted to the clinic

Images